Conformational comparability of factor IX-Fc fusion protein, factor IX, and purified Fc fragment in the absence and presence of calcium

Journal of Pharmaceutical Sciences

Volumn 101, Issue 5, 2012, Pages 1688-1700

  Houde, Damian ^a   Berkowitz, Steven A ^a  

^a BIOGEN   (United States)

Author keywords

Biotechnology; Calcium binding; Calorimetry (DSC); Coagulation factors; Fusion protein; Hydrogen deuterium exchange; Mass spectrometry; Protein binding; Protein structure

Indexed keywords

BLOOD CLOTTING FACTOR 9; CALCIUM; CALCIUM BINDING PROTEIN; DEUTERIUM; FC RECEPTOR; HYBRID PROTEIN; HYDROGEN; IMMUNOGLOBULIN FC FRAGMENT; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 9 FC FUSION PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOPHYSICS; BLOOD CLOTTING; CALCIUM BINDING; CONTROLLED STUDY; DEUTERIUM HYDROGEN EXCHANGE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CONFORMATION; DRUG EFFICACY; DRUG FORMULATION; DRUG PURIFICATION; GEL PERMEATION CHROMATOGRAPHY; HUMAN; INJECTION; MASS SPECTROMETRY; MOLECULAR DYNAMICS; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; CHEMISTRY;

CALCIUM; CALORIMETRY, DIFFERENTIAL SCANNING; FACTOR IX; IMMUNOGLOBULIN FC FRAGMENTS; MASS SPECTROMETRY; PROTEIN CONFORMATION;

EID: 84864312374     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23064     Document Type: Article

References (48)

1. Reichert JM. 2006. Trends in US approvals: New biopharmaceuticals and vaccines. Trends Biotechnol 24(7):293-298.
2. Paradise J. 2011. Foreword: Follow-on biologics: Implementation challenges and opportunities. Seton Hall Law Rev 41(2):501-510.
3. Alconcel SNS, Baas AS, Maynard HD. 2011. FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polymer Chem 2(7):1442-1448.
4. Cree B. 2006. Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 12(4):171-178.
5. Talamonti M, Spallone G, Di Stefani A, Costanzo A, Chimenti S. 2011. Efalizumab. Expert Opin Drug Saf 10(2):239-251.
6. Beck A, Reichert JM. 2011. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3(5):415-416.
7. Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols TC, Bitonti AJ. 2010. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 115(10):2057-2064.
8. Furie B, Furie BC. 1988. The molecular basis of blood coagulation. Cell 53(4):505-518.
9. Mackman N. 2008. Tissue-specific hemostasis: Role of tissue factor. J Thromb Haemost 6(2):303-305.
10. Mackman N, Tilley RE, Key NS. 2007. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 27(8):1687-1693.
11. Thompson AR. 1986. Structure, function, and molecular defects of factor IX. Blood 67(3):565-572.
12. Castaldo G, D'Argenio V, Nardiello P, Zarrilli F, Sanna V, Rocino A, Coppola A, Di Minno G, Salvatore F. 2007. Haemophilia A: Molecular insights. Clin Chem Lab Med 45(4):450-461.
13. Veltkamp JJ, Meilof J, Remmelts HG, van der Vlerk D, Loeliger EA. 1970. Another genetic variant of haemophilia B: Haemophilia B Leyden. Scand J Haematol 7(2):82-90.
14. Connor JM, Pettigrew AF, Hann IM, Forbes CD, Lowe GD, Affara NA. 1985. Application of an intragenic genomic probe to genetic counselling for haemophilia B in the west of Scotland. J Med Genet 22(6):441-446.
15. O'Connell NM. 2003. Factor XI deficiency-From molecular genetics to clinical management. Blood Coagul Fibrinolysis 14(Suppl 1):S59-S64.
16. Giangrande P. 2005. Haemophilia B: Christmas disease. Expert Opin Pharmacother 6(9):1517-1524.
17. Moore S, Stein WH. 1973. Chemical structures of pancreatic ribonuclease and deoxyribonuclease. Science 180(85):458-464.
18. Anfinsen CB. 1973. Principles that govern the folding of protein chains. Science 181(96):223-230.
19. Schmidt AE, Bajaj SP. 2003. Structure-function relationships in factor IX and factor IXa. Trends Cardiovasc Med 13(1):39-45.
20. Lenting PJ, Christophe OD, Maat H, Rees DJ, Mertens K. 1996. Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding. J Biol Chem 271(41):25332-25337.
21. Shikamoto Y, Morita T, Fujimoto Z, Mizuno H. 2003. Crystal structure of Mg2+- and Ca2+-bound Gla domain of factor IX complexed with binding protein. J Biol Chem 278(26):24090-24094.
22. Bajaj SP. 1982. Cooperative Ca2+ binding to human factor IX. Effects of Ca2+ on the kinetic parameters of the activation of factor IX by factor XIa. J Biol Chem 257(8):4127-4132.
23. Li H, Bai S, Wei JY, Berkowitz SA, Brader ML. 2011. Calcium binding to a factor IX Fc fusion protein and effects on higher-order structure. J Pharm Sci 100:4597-4606.
24. Lindquist PA, Fujikawa K, Davie EW. 1978. Activation of bovine factor IX (Christmas factor) by factor XIa (activated plasma thromboplastin antecedent) and a protease from Russell's viper venom. J Biol Chem 253(6):1902-1909.
25. Yuan QP, Walke EN, Sheehan JP. 2005. The factor IXa heparin-binding exosite is a cofactor interactive site: Mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin. Biochemistry 44(9):3615-3625.
26. Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. 1995. X-ray structure of clotting factor IXa: Active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci U S A 92(21):9796-9800.
27. Freedman SJ, Furie BC, Furie B, Baleja JD. 1995. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX. Biochemistry 34(38):12126-12137.
28. Vysotchin A, Medved LV, Ingham KC. 1993. Domain structure and domain-domain interactions in human coagulation factor IX. J Biol Chem 268(12):8436-8446.
29. Wales TE, Engen JR. 2006. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom Rev 25(1):158-170.
30. Houde D, Berkowitz SA, Engen JR. 2011. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. J Pharm Sci 100(6):2071-2086.
31. Bobst CE, Kaltashov IA. 2011. Advanced mass spectrometry-based methods for the analysis of conformational integrity of biopharmaceutical products. Curr Pharm Biotechnol 12:1517-1529.
32. Chen G, Warrack BM, Goodenough AK, Wei H, Wang-Iverson DB, Tymiak AA. 2011. Characterization of protein therapeutics by mass spectrometry: Recent developments and future directions. Drug Discov Today 16(1-2):58-64.
33. Burkitt W, Domann P, O'Connor G. 2010. Conformational changes in oxidatively stressed monoclonal antibodies studied by hydrogen exchange mass spectrometry. Protein Sci 19(4):826-835.
34. Bruylants G, Wouters J, Michaux C. 2005. Differential scanning calorimetry in life science: Thermodynamics, stability, molecular recognition and application in drug design. Curr Med Chem 12(17):2011-2020.
35. Houde D, Peng Y, Berkowitz SA, Engen JR. 2010. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 9(8):1716-1728.
36. Wales TE, Fadgen KE, Gerhardt GC, Engen JR. 2008. High-speed and high-resolution UPLC separation at zero degrees celsius. Anal Chem 80(17):6815-6820.
37. Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ. 2006. Absolute quantification of proteins by LCMSE: A virtue of parallel MS acquisition. Mol Cell Proteomics 5(1):144-156.
38. Tischenko VM, Abramov VM, Zav'yalov VP. 1998. Investigation of the cooperative structure of Fc fragments from myeloma immunoglobulin G. Biochemistry 37(16):5576-5581.
39. Ghirlando R, Lund J, Goodall M, Jefferis R. 1999. Glycosylation of human IgG-Fc: Influences on structure revealed by differential scanning micro-calorimetry. Immunol Lett 68(1):47-52.
40. McLean FC, Hastings AB. 1935. The state of calcium in the fluids of the body. J Biol Chem 108(1):285-321.
41. Robertson WG. 1976. Measurement of ionised calcium in body fluids-A review. Ann Clin Biochem 13(6):540-548.
42. Englander SW, Kallenbach NR. 1983. Hydrogen exchange and structural dynamics of proteins and nucleic acids. Q Rev Biophys 16(4):521-655.
43. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. 2001. Crystal structure of a neutralizing human IGG against HIV-1: A template for vaccine design. Science 293(5532):1155-1159.
44. Krieger E, Koraimann G, Vriend G. 2002. Increasing the precision of comparative models with YASARA NOVA-A self-parameterizing force field. Proteins 47(3):393-402.
45. Huang M, Furie BC, Furie B. 2004. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J Biol Chem 279(14):14338-14346.
46. Souillac PO. 2005. Biophysical characterization of insoluble aggregates of a multi-domain protein: An insight into the role of the various domains. J Pharm Sci 94(9):2069-2083.
47. Ionescu RM, Vlasak J, Price C, Kirchmeier M. 2008. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97(4):1414-1426.
48. Eglen RM, Reisine T, Roby P, Rouleau N, Illy C, Bosse R, Bielefeld M. 2008. The use of AlphaScreen technology in HTS: Current status. Curr Chem Genomics 1:2-10.